Company Login
Site Newsletter
Welcome to PharmiWeb.com
Latest Press Releases
- Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program
27 Aug 08
PharmiWeb - FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia
27 Aug 08
PharmiWeb - Positive Phase II Results with Visonac (TM) for acne
27 Aug 08
Citigate Dewe Rogerson - Anatstat Health Education Wins Eight Awards in 2008 National Health Information Awards Program
26 Aug 08
- Aesica Opens New Global Headquarters
26 Aug 08
Citigate Dewe Rogerson
Latest News
A&D Pharma Holdings N.V. Announces Management ChangeReuters
28 Aug 08 , 06:26
SkyePharma PLC -- Interim ResultsStreet Insider
28 Aug 08 , 06:18
SkyePharma PLC -- Interim ResultsMarket Wire via MSN Money
28 Aug 08 , 06:15
Galapagos acquires Sareum's assets in drug discovery servicesPharmaBiz
28 Aug 08 , 06:12
SkyePharma PLC -- Interim ResultsStockwatch
28 Aug 08 , 06:09
Latest Events
- SIX SIGMA GREEN BELT CERTIFICATION WORKSHOP
29 Aug 08 - 31 Aug 08 - Stem Cells Europe 2008
01 Sep 08 - 02 Sep 08 - EU DRUGS REGULATION FROM DISCOVERY TO MARKETING AND BEYOND
02 Sep 08 - 05 Sep 08
pharmiweb.com today | 28 August 2008
ANTHERA PHARMACEUTICALS ADVANCES GLOBAL DEVELOPMENT STRATEGY FOR VARESPLADIB IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH THE INITIATION OF FRANCIS TRIAL
SAN MATEO, CA – August 25, 2008 – Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced the initiation of the FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) clinical trial designed to examine the impact of varespladib when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event.
The FRANCIS trial is designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk. It will enroll up to 500 patients that will be treated for a minimum of six months. The study will be conducted at sites in North America and Europe. FRANCIS will provide insight into the prevention of secondary Major Adverse Cardiovascular Events (MACE) over the duration of the trial. In this study, MACE is defined as a composite endpoint consisting of cardiovascular death, non-fatal stroke, non-fatal myocardial infarction, unstable angina, and a subset of revascularization following the initial event.
Latest Features
Dont forget - Job Alerts by Email
27 Aug 08
Whether you are looking for pharma sales jobs, clinical research jobs, or any other pharmaceutical job, with thousands of jobs in the PharmiWeb.
What Is Psoriasis?
14 Aug 08
This feature 'What is Psoriasis?' is one of three features that focuses on the topic of skin conditions.
What Is Eczema?
14 Aug 08
This feature 'What is Eczema?' is one of three features that focuses on the topic of skin conditions.
Latest Poll
